Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
intismeran autogene + BCG
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravesical (bcg), Intramuscular (intismeran Autogene)
01
Overview
**Intismeran autogene + BCG** is a combination investigational immunotherapy regimen for high-risk non-muscle invasive bladder cancer (HR NMIBC). Intismeran autogene (V940, also known as mRNA-4157) is a personalized mRNA-based cancer vaccine that encodes patient-specific neoantigens, designed to stimulate the immune system to recognize and attack tumor cells. Bacillus Calmette-Guerin (BCG) is an established live attenuated strain of Mycobacterium bovis used intravesically as immunotherapy in bladder cancer, acting mainly by activating local immune responses in the bladder. In combination, intismeran autogene aims to enhance systemic anti-tumor immunogenicity, while BCG provides potent local immune stimulation, potentially leading to improved outcomes in NMIBC by reducing recurrence and progression rates[2][3][5][6].
- Other names
- intismeran autogene + Bacillus Calmette-Guerinintismeran autogene + BCG
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)Neoantigen-MHC class I complexNeoantigen-specific T-cell receptorpMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on intismeran autogene + BCG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on intismeran autogene + BCG.